Transcript
Announcer:
This is Project Oncology on ReachMD. Today, Dr. Angel Qin will discuss recent and emerging therapeutic advances in ALK-positive non-small cell lung cancer. She’s a Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School. Let’s hear from her now.
Dr. Qin:
I think we've seen a lot of exciting data that's come out more recently in the ALK non-small cell lung cancer space. First of all, we saw the benefit in terms of durability with respect to lorlatinib in the frontline. We saw that at seven years, the median progression-free survival had still not been reached. We saw that this durability was not only extracranially, but also within the brain, and we know that brain metastases are such a significant burden for our patients.
We're also seeing some new ALK inhibitors being developed and tested in this space, I think most notably the neladalkib. We saw some data in terms of its activity in the treated space for patients who had progressed on other ALK TKIs and even chemotherapy. We saw some favorable data and activity there. And of course, there's ongoing studies now to understand if there's a role for the neladalkib in the frontline. So a lot of exciting developments in the metastatic space.
And even in the nonmetastatic space, we've seen now studies looking at whether we should be using these ALK TKIs even earlier in the treatment of non-small cell lung cancer. So we're looking at using alectinib and lorlatinib in the neoadjuvant setting, so prior to surgery. There, of course, is already an approval for alectinib in the adjuvant setting, so post-surgery for ALK-positive. And so I think there's just a lot of activity in this space, and it's really exciting for our patients.
Announcer:
That was Dr. Angel Qin discussing current and emerging advances in the treatment of ALK-positive non-small cell lung cancer. To access this and other episodes in our series, visit Project Oncology on ReachMD.com, where you can Be Part of the Knowledge. Thanks for listening!
